Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeremy M Shefner

Showing results (51-60 of 105) with videos related to

Pageof 11
Sort By:
Neurobiology of Disease|August 9, 2005
Degeneration of respiratory motor neurons in the SOD1 G93A transgenic rat model of ALSJerònia Lladó, Christine Haenggeli, Andrea Pardo, et al.
Muscle & Nerve|March 19, 2025
Akt Activation With IPL344 Treatment for Amyotrophic Lateral Sclerosis: First in Human, Open-Label StudyMarc Gotkine, David A Schoenfeld, Ilana Cohen, et al.
Muscle & Nerve|November 25, 2010
Characterizing spinal muscular atrophy with electrical impedance myographySeward B Rutkove, Jeremy M Shefner, Matt Gregas, et al.
Journal of Neuromuscular Diseases|May 5, 2025
Application of the ENCALS predictive survival model in assessing the effect of the 24/44 inclusion criteria in FORTITUDE-ALSTyrell Simkins Lead, Jeremy M Shefner, Stuart Kupfer, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|June 27, 2025
Participant, site personnel and sponsor perspectives on decentralized trial features in COURAGE-ALS: a randomized clinical trialStacy A Rudnicki, Paulos Gebrehiwet, Stuart Kupfer, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|September 29, 2018
Reducing sample size requirements for future ALS clinical trials with a dedicated electrical impedance myography systemJeremy M Shefner, Seward B Rutkove, James B Caress, et al.
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|April 26, 2021
Putting the patient first: The validity and value of surface-based electrical impedance myography techniquesSeward B Rutkove, Pushpa Narayanaswami, W David Arnold, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|February 7, 2018
VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristicsJinsy A Andrews, Merit E Cudkowicz, Orla Hardiman, et al.
JAMA Neurology|November 29, 2017
Association Between Decline in Slow Vital Capacity and Respiratory Insufficiency, Use of Assisted Ventilation, Tracheostomy, or Death in Patients With Amyotrophic Lateral SclerosisJinsy A Andrews, Lisa Meng, Sarah F Kulke, et al.
Annals of Clinical and Translational Neurology|September 11, 2020
Efficacy of Ciprofloxacin/Celecoxib combination in zebrafish models of amyotrophic lateral sclerosisHagit Goldshtein, Alexandre Muhire, Virginie Petel Légaré, et al.
Pageof 11

Showing results (51-60 of 105) with videos related to

Sort By:
Pageof 11
Neurobiology of Disease|August 9, 2005
Degeneration of respiratory motor neurons in the SOD1 G93A transgenic rat model of ALSJerònia Lladó, Christine Haenggeli, Andrea Pardo, et al.
Muscle & Nerve|March 19, 2025
Akt Activation With IPL344 Treatment for Amyotrophic Lateral Sclerosis: First in Human, Open-Label StudyMarc Gotkine, David A Schoenfeld, Ilana Cohen, et al.
Muscle & Nerve|November 25, 2010
Characterizing spinal muscular atrophy with electrical impedance myographySeward B Rutkove, Jeremy M Shefner, Matt Gregas, et al.
Journal of Neuromuscular Diseases|May 5, 2025
Application of the ENCALS predictive survival model in assessing the effect of the 24/44 inclusion criteria in FORTITUDE-ALSTyrell Simkins Lead, Jeremy M Shefner, Stuart Kupfer, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|June 27, 2025
Participant, site personnel and sponsor perspectives on decentralized trial features in COURAGE-ALS: a randomized clinical trialStacy A Rudnicki, Paulos Gebrehiwet, Stuart Kupfer, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|September 29, 2018
Reducing sample size requirements for future ALS clinical trials with a dedicated electrical impedance myography systemJeremy M Shefner, Seward B Rutkove, James B Caress, et al.
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|April 26, 2021
Putting the patient first: The validity and value of surface-based electrical impedance myography techniquesSeward B Rutkove, Pushpa Narayanaswami, W David Arnold, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|February 7, 2018
VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristicsJinsy A Andrews, Merit E Cudkowicz, Orla Hardiman, et al.
JAMA Neurology|November 29, 2017
Association Between Decline in Slow Vital Capacity and Respiratory Insufficiency, Use of Assisted Ventilation, Tracheostomy, or Death in Patients With Amyotrophic Lateral SclerosisJinsy A Andrews, Lisa Meng, Sarah F Kulke, et al.
Annals of Clinical and Translational Neurology|September 11, 2020
Efficacy of Ciprofloxacin/Celecoxib combination in zebrafish models of amyotrophic lateral sclerosisHagit Goldshtein, Alexandre Muhire, Virginie Petel Légaré, et al.
Pageof 11